Πλοήγηση ανά Θέμα "nivolumab"
Αποτελέσματα 1-13 από 13
-
Anti-PD1 Immunotherapy for Metastatic Renal Cancer Boosted Humoral Immunity in a Hemodialysis Patient
(2021)Immune checkpoint inhibitors by blocking specific inhibitory pathways induce T-cell-mediated tumor lysis. However, many remain to be elucidated about their effect on human humoral immunity. We evaluated the effect of the ... -
Immune checkpoint inhibitor-induced musculoskeletal manifestations
(2021)Immune checkpoint inhibitors (ICI) associate with a wide range of immune-related adverse events (Ir-AE), including musculoskeletal manifestations. We aimed at identifying all studies reporting musculoskeletal Ir-AE. An ... -
Immune-based treatment re-challenge in renal cell carcinoma: A systematic review and meta-analysis
(2022)Introduction: The use of immune checkpoint inhibitors (ICIs) as a front-line treatment for metastatic renal cell carcinoma (RCC) has significantly improved patient’ outcome. However, little is known about the efficacy or ... -
Immunotherapy Efficacy in the Initial Lines of Treatment in Advanced Upper Gastrointestinal Malignancies: A Systematic Review of the Literature
(2021)Background: The therapeutic role of immune checkpoint inhibitors (ICIs) has represented the cutting edge of clinical research in upper gastrointestinal (GI) malignancies, with these agents now included in the armamentarium ... -
Immunotherapy of Cancer: Developments and Reference Points, an Unorthodox Approach
(2019)Oncology is currently a sector of medical science with accelerated progress due to rapid technological development, the advancement in molecular biology, and the invention of many innovative therapies. Immunotherapy partially ... -
Myeloid-derived suppressor cells: Major figures that shape the immunosuppressive and angiogenic network in cancer
(2019)Myeloid-derived suppressor cells (MDSCs) constitute a vast population of immature myeloid cells implicated in various conditions. Most notably, their role in cancer is of great complexity. They exert immunosuppressive ... -
Nivolumab as first-line treatment in non-small cell lung cancer patients-key factors: Tumor mutation burden and PD-L1 ≥50%
(2018)[No abstract available] -
Oligometastasis and local ablation in the era of systemic targeted and immunotherapy
(2020)Background: During these last years, new agents have dramatically improved the survival of the metastatic patients. Oligometastases represent a continuous field of interest in which the integration of metastases-directed ... -
PD-1 and PD-L1 as immunotherapy targets and biomarkers in non-small cell lung cancer
(2019)The integration of immunotherapeutic agents in the treatment of non-small cell lung cancer (NSCLC) has revolutionized the approach of the prevalent type of lung cancer. Although PD-1 and its ligands (PD-L1 and PD-L2) are ... -
Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group
(2022)Background: Data on the safety and efficacy of immune checkpoint inhibitors (ICI) in patients with concurrent autoimmune diseases (AID) are limited. Methods: We performed a retrospective multicenter review of medical records ...